SynthesisActa neuropsychiatrica2026
Parenteral clomipramine for depression or obsessive-compulsive disorder: a systematic review and meta-analysis.
Synthesis in Acta neuropsychiatrica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In severe cases of depression and obsessive-compulsive disorder (OCD), clomipramine is sometimes administered parenterally. This systematic review aimed to investigate whether parenteral clomipramine is superior to oral clomipramine or other treatments, primarily in terms of reducing depressive/OCD symptoms within two weeks (CRD420250654029). Medline, Embase, the Cochrane Library, and PsycInfo were searched for relevant publications. Randomized controlled trials (RCTs) without a high risk of bias formed the primary basis for the conclusions. Meta-analyses were performed when applicable. Certainty of evidence was assessed according to GRADE. The literature search identified 4973 unique publications, whereof 14 RCTs contributed data regarding the question at issue in this systematic review. The evidence synthesis revealed that parenteral clomipramine may not be superior to oral administration in terms of reducing depressive symptoms within two weeks, but a clinically relevant effect cannot be excluded (low certainty of evidence; five RCTs including 70 patients; mean difference of change in Hamilton depression rating scale scores (meta-analysis based on three RCTs): -1.27 (95% confidence interval: -3.09 to 0.54; 2, I2 = 22%). Regarding patients with OCD, no conclusion could be drawn (very low certainty of evidence; two RCTs including 47 patients; meta-analysis not conducted due to heterogeneity). Regarding comparisons with other treatments, the available RCT (depression) did not allow for conclusions, or no RCTs (OCD) were available. Current evidence indicates that parenteral administration of clomipramine may not be favourable compared to oral administration, and RCTs with relevant comparisons such as electroconvulsive therapy and ketamine are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.